Publications by authors named "K Lombardo"
Background: Sarcomatoid urothelial cancer of the bladder (SBC) is a rare, but aggressive histological subtype for which novel treatments are needed.
Objective: We evaluated the clinical activity and safety of neoadjuvant cisplatin plus gemcitabine plus docetaxel (CGD) in muscle-invasive patients with SBC and assessed SBC tumor biology by whole transcriptome RNA sequencing.
Methods: A single-institution, retrospective analysis of muscle-invasive SBC patients treated with neoadjuvant CGD with molecular analysis.
Introduction: Immune checkpoint inhibitors (ICIs) are approved for advanced urothelial cancer alone and as first-line in combination with enfortumab vedotin. Platinum based chemotherapy which is another frontline choice is often not a treatment option for older patients due to comorbidities that increase with age. Despite ICIs being better tolerated compared to traditional chemotherapy little is known about their efficacy and toxicity in patients ≥ 90 years due to the rarity of this population in clinical trials.
View Article and Find Full Text PDFArticle Synopsis
- Glutamine metabolism is crucial in tumor microenvironments and influences how the immune system responds to tumors.
- The glutamine-antagonist prodrug JHU083 effectively inhibits growth in urologic tumors by reprogramming tumor-associated macrophages (TAMs) and enhancing immune responses.
- JHU083 not only reduces metabolic activity in tumor cells but also helps alter the behavior of T cells, leading to a decrease in cancer cell growth and an improved antitumor environment.
Background And Objective: The timing of perioperative nephrotoxic chemotherapy for upper tract urothelial carcinoma (UTUC) remains controversial and strongly depends on predicted platinum eligibility after radical nephroureterectomy (RNU). The study objective was to develop and validate a multivariable nomogram to predict estimated glomerular filtration rate (eGFR) following RNU.
Methods: This was a multi-institutional retrospective study of patients with UTUC treated with RNU from 2000 to 2020 at seven high-volume referral centers.
Article Synopsis
- Researchers studied tiny particles called small extracellular vesicles (sEVs) to find out if they can show different types of bladder cancer.
- They used special techniques to get and check these sEVs from bladder tissue, urine, and blood, finding that urine sEVs are mostly one type and blood sEVs another, even if the tissue says something different.
- Four new important mRNA markers (FAM71E2, OR4K5, FAM138F, KRTAP26-1) were found that might help tell us more about bladder cancer, but more studies are needed to see if these markers work well in more patients.